(RTTNews) - Eli Lilly and Company (LLY) on Monday announced positive Phase 3 results showing that its oral obesity drug Foundayo (orforglipron) significantly reduced obstructive sleep apnea (OSA) severity in adults with obesity or overweight.
We show the main point publicly. Create a free account to continue reading the full article, save it, discuss it, and connect it with market and OSINT context.